These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 30318080)

  • 1. Nimotuzumab: beyond the EGFR signaling cascade inhibition.
    Mazorra Z; Chao L; Lavastida A; Sanchez B; Ramos M; Iznaga N; Crombet T
    Semin Oncol; 2018 Jan; 45(1-2):18-26. PubMed ID: 30318080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.
    Kol A; Terwisscha van Scheltinga A; Pool M; Gerdes C; de Vries E; de Jong S
    Oncotarget; 2017 Jul; 8(28):45432-45446. PubMed ID: 28467975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
    Berger C; Krengel U; Stang E; Moreno E; Madshus IH
    J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.
    Mazorra Z; Lavastida A; Concha-Benavente F; Valdés A; Srivastava RM; García-Bates TM; Hechavarría E; González Z; González A; Lugiollo M; Cuevas I; Frómeta C; Mestre BF; Barroso MC; Crombet T; Ferris RL
    Front Pharmacol; 2017; 8():382. PubMed ID: 28674498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.
    Kawaguchi Y; Kono K; Mimura K; Sugai H; Akaike H; Fujii H
    Int J Cancer; 2007 Feb; 120(4):781-7. PubMed ID: 17096332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
    Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
    Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
    Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
    Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.
    Okamoto W; Yoshino T; Takahashi T; Okamoto I; Ueda S; Tsuya A; Boku N; Nishio K; Fukuoka M; Yamamoto N; Nakagawa K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1063-71. PubMed ID: 24046058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.
    Kubach J; Hubo M; Amendt C; Stroh C; Jonuleit H
    Int J Cancer; 2015 Feb; 136(4):821-30. PubMed ID: 24947844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies.
    Chew HY; De Lima PO; Gonzalez Cruz JL; Banushi B; Echejoh G; Hu L; Joseph SR; Lum B; Rae J; O'Donnell JS; Merida de Long L; Okano S; King B; Barry R; Moi D; Mazzieri R; Thomas R; Souza-Fonseca-Guimaraes F; Foote M; McCluskey A; Robinson PJ; Frazer IH; Saunders NA; Parton RG; Dolcetti R; Cuff K; Martin JH; Panizza B; Walpole E; Wells JW; Simpson F
    Cell; 2020 Mar; 180(5):895-914.e27. PubMed ID: 32142680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
    Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
    J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
    Diaz Miqueli A; Blanco R; Garcia B; Badia T; Batista AE; Alonso R; Montero E
    Hybridoma (Larchmt); 2007 Dec; 26(6):423-31. PubMed ID: 18158788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody].
    Shimodaira H; Komine K; Soeda H; Ishioka C
    Gan To Kagaku Ryoho; 2010 May; 37(5):795-8. PubMed ID: 20495309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.
    Schneider-Merck T; Lammerts van Bueren JJ; Berger S; Rossen K; van Berkel PH; Derer S; Beyer T; Lohse S; Bleeker WK; Peipp M; Parren PW; van de Winkel JG; Valerius T; Dechant M
    J Immunol; 2010 Jan; 184(1):512-20. PubMed ID: 19949082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.